title: Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes.
abstract: To examine the association between fatty acid binding protein 4 (FABP4) and pre-eclampsia risk in women with type 1 diabetes.
  
  
  
  Serum FABP4 was measured in 710 women from the Diabetes and Pre-eclampsia Intervention Trial (DAPIT) in early pregnancy and in the second trimester (median 14 and 26 weeks' gestation, respectively).
  
  
  
  FABP4 was significantly elevated in early pregnancy (geometric mean 15.8 ng/mL [interquartile range 11.6-21.4] vs. 12.7 ng/mL [interquartile range 9.6-17]; P < 0.001) and the second trimester (18.8 ng/mL [interquartile range 13.6-25.8] vs. 14.6 ng/mL [interquartile range 10.8-19.7]; P < 0.001) in women in whom pre-eclampsia later developed. Elevated second-trimester FABP4 level was independently associated with pre-eclampsia (odds ratio 2.87 [95% CI 1.24-6.68], P = 0.03). The addition of FABP4 to established risk factors significantly improved net reclassification improvement at both time points and integrated discrimination improvement in the second trimester.
  
  
  
  Increased second-trimester FABP4 independently predicted pre-eclampsia and significantly improved reclassification and discrimination. FABP4 shows potential as a novel biomarker for pre-eclampsia prediction in women with type 1 diabetes.
authors.affiliation: Centre for Public Health, Queen's University Belfast, Belfast, U.K.
authors.forename: Amy C
authors.initials: AC
authors.lastname: Wotherspoon
authors.affiliation: Centre for Public Health, Queen's University Belfast, Belfast, U.K.
authors.forename: Ian S
authors.initials: IS
authors.lastname: Young
authors.affiliation: Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, U.K.
authors.forename: David R
authors.initials: DR
authors.lastname: McCance
authors.affiliation: Centre for Public Health, Queen's University Belfast, Belfast, U.K.
authors.forename: Chris C
authors.initials: CC
authors.lastname: Patterson
authors.affiliation: Department of Obstetrics, Saint Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, U.K.
authors.forename: Michael J A
authors.initials: MJ
authors.lastname: Maresh
authors.affiliation: Department of Diabetes, Aberdeen Royal Infirmary, Aberdeen, U.K.
authors.forename: Donald W M
authors.initials: DW
authors.lastname: Pearson
authors.affiliation: Department of Diabetes, St John's Hospital at Howden, West Lothian, U.K.
authors.forename: James D
authors.initials: JD
authors.lastname: Walker
authors.affiliation: Centre for Public Health, Queen's University Belfast, Belfast, U.K. v.holmes@qub.ac.uk.
authors.forename: Valerie A
authors.initials: VA
authors.lastname: Holmes
mesh_terms: D015992:Body Mass Index; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000175:diagnosis; D004311:Double-Blind Method; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D005819:Genetic Markers; D006801:Humans; D016015:Logistic Models; D015337:Multicenter Studies as Topic; D011225:Pre-Eclampsia / Q000097:blood* / Q000175:diagnosis; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D005819:Genetic Markers